Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan

Abstract Clinical trials showed pangenotypic direct-acting antivirals’ (DAAs) excellent efficacy and safety when treating hepatitis C virus (HCV). Two pangenotypic regimens were examined, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), in a real-world Taiwanese setting, incl...

Full description

Bibliographic Details
Main Authors: Kao-Chi Chang, Shui-Yi Tung, Kuo-Liang Wei, Chen-Heng Shen, Yung-Yu Hsieh, Wei-Ming Chen, Yi-Hsing Chen, Chun-Hsien Chen, Chi-Wei Yen, Huang-Wei Xu, Wei-Lin Tung, Chao-Hung Hung, Sheng-Nan Lu, Te-Sheng Chang
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-93095-x

Internet

https://doi.org/10.1038/s41598-021-93095-x

Similar Items